Navigation Links
Blood Substitute Found Safe in Large Phase III Trial
Date:6/21/2008

It worked best in those under 80, could ease expected worldwide shortfall of supplies

FRIDAY, June 20 (HealthDay News) -- A blood substitute product called HBOC-201 proved safe and effective in a six-week Phase III multi-center clinical trial, a new study reports.

In all, 688 patients, ages 18 and older, who had elective orthopedic surgery initially received either one unit of blood (about one pint) or an equivalent one unit (65 grams) of HBOC-201, which is a hemoglobin-based oxygen carrier. Patients could receive up to 10 units of the blood substitute or unlimited blood transfusions over six days. The patients were evaluated daily and six weeks after their surgery.

Most of the 350 patients receiving the blood substitute used an average of five or less units, while the 338 patients receiving blood used less than two units on average.

"We found that we eliminated the need for blood transfusions for 59 percent of the 350 patients who received the blood substitute. The blood substitute worked best in those under 80 years old with a moderate transfusion need," study author Dr. Colin F. Mackenzie, professor and former director of the National Center for Trauma and EMS, University of Maryland School of Medicine, said in a prepared statement.

The blood substitute did not work as well as blood in patients over age 80 with more acute health issues and higher transfusion needs, and many of these patients were switched to regular blood.

Twenty-one of the older patients who received the blood substitute suffered a number of cardiac and central nervous system problems. Analysis revealed that these were due to advanced age, heart failure or possibly under-treatment, according to the researchers.

Death rates in patients with moderate transfusion needs who received either blood or the blood substitute were 1 percent. Death rates among patients with high transfusion needs were 5 percent in the blood substitute group and 3 percent in the blood group.

Common temporary side effects noted in patients who received the blood substitute included skin discoloration interpreted as jaundice, elevated blood pressure, and increased levels of the enzymes troponin and lipase.

The study, published in the June issue of the Journal of Trauma: Injury, Infection, and Critical Care, was funded by the Biopure Corporation, which makes HBOC-201.

The need to develop an alternative to red blood cells is being driven by a predicted shortfall of more than four million units of blood worldwide, according to background information in the study.

More information

America's Blood Centers has more about blood transfusions.



-- Robert Preidt



SOURCE: UCLA Health Sciences, news release, June 10, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Low Blood Sodium Predicts Mortality in PAH Patients
2. MetLife Foundation Partners with New York Blood Center to Introduce Donor Coach to New York Boroughs
3. Cord Blood America Says Pennsylvania Joins New York and California in Informing Parents of the Advantages of Umbilical Cord Blood Storage
4. New cancer treatment targets both tumor cells and blood vessels
5. Computers as safe as medical experts in prescribing blood thinning drugs
6. Tracking Top Number in Blood Pressure May Be Enough
7. High Blood Pressure in Kids Tracks Into Adulthood
8. ARKRAY USA Nationally Launches GLUCOCARD(TM) X-METER Blood Glucose Monitoring System
9. Spotting Vitamin-D Deficiency in the Absence of Symptoms: ZRT Laboratorys New, One-of-a-Kind Blood Spot Test Answers the Call for Early Detection of Rapidly Rising D-Deficiencies
10. AARP Michigan and American Red Cross Partner to Help Save Lives Through Blood Donation Drive
11. Cancer-killing viruses influence tumor blood-vessel growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: